Topical analgesics: lidocaine, capsaicin and topical NSAIDs
Pharmacotherapy · G3d · Reviewed by a board-certified pain physician on November 2, 2026
Bottom line
Topicals put the drug where the pain is and keep systemic exposure low. Know the lidocaine patch 12-hour rule, capsaicin 8% application times and repeat interval, and that topical NSAIDs come before oral NSAIDs in knee osteoarthritis.
Key points
- Lidocaine 5% patch: three patches, 12 hours. Apply up to three patches to intact skin over the most painful area, once for up to 12 hours in any 24-hour period; absorption rises with area and duration 1.
- Topicals are second-line for neuropathic pain. The 2025 NeuPSIG update gives capsaicin 8% patches, capsaicin cream and lidocaine 5% plasters weak, second-line recommendations 2; the 2015 version limited topicals to peripheral pain with a local pain generator 6.
- Lidocaine in frail patients: second line since 2025. NeuPSIG 2015 allowed lidocaine patches first line when systemic drugs raised safety concerns, particularly in frail older patients 6; the 2025 update ranks them second line, with very low certainty evidence (NNT 14.5) 2.
- Capsaicin 8% works by defunctionalizing nociceptors. It activates TRPV1, causing initial burning, then reduces TRPV1-expressing nerve endings, which re-emerge over several months 3.
- Know capsaicin 8% application times. Up to four systems for 30 minutes on the feet in diabetic neuropathy, or 60 minutes for postherpetic neuralgia, repeated no more often than every 3 months, on intact skin 3.
- Topical NSAIDs before oral in knee osteoarthritis. ACR/AF strongly recommends topical NSAIDs and advises considering them before oral NSAIDs 4. Topical diclofenac has a more favorable renal profile than oral, but at-risk kidneys still need monitoring 5.
Watch for
High-yield for the exam
- Lidocaine patch schedule: 12 hours on, 12 hours off, maximum three patches 1.
- Used lidocaine patches still contain drug; fold them and keep them away from children and pets 1.
- NeuPSIG 2025 NNTs: capsaicin 8% patch 13.2; capsaicin cream 6.1 and lidocaine 5% 14.5, both very low certainty 2.
- The burning during capsaicin application reflects TRPV1 activation before nociceptor defunctionalization 3.
- Capsaicin 8% can be repeated every 3 months as pain returns, not sooner 3.
- Topical diclofenac reduces but does not abolish renal risk in high-risk patients 5.
- NeuPSIG 2015 proposed topical treatment only for peripheral neuropathic pain with a presumed local pain generator, not for central pain 6.
- Topical NSAIDs follow the ACR principle that therapies with the least systemic exposure are preferable 4.
Numbers to know
Common traps
- Leaving lidocaine patches on around the clock to extend relief 1.
- Repeating capsaicin 8% monthly because pain returns early 3.
- Starting oral NSAIDs first in an older adult with knee osteoarthritis and renal risk 4.
- Expecting a topical to help diffuse or central neuropathic pain without a local generator 6.
Practise this topic
5 more questions on this topic in the full question bank, with explanations and sources.
Sources
- US Food and Drug Administration. LIDODERM (lidocaine patch 5%) prescribing information. DailyMed, 2023. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db0092f5-02
- Soliman N, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol, 2025. pubmed.ncbi.nlm.nih.gov/40252663/
- US Food and Drug Administration. QUTENZA (capsaicin) 8% topical system prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad
- Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol, 2020. pmc.ncbi.nlm.nih.gov/articles/PMC10518852/
- Coșovanu EO, et al. Renal safety of topical diclofenac in adults with increased renal risk: a systematic review. Medicina (Kaunas), 2026. pmc.ncbi.nlm.nih.gov/articles/PMC13515200/
- Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol, 2015. pmc.ncbi.nlm.nih.gov/articles/PMC4493167/
Related topics
Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.